Home
SKYE
SKYE News

Latest Skye Bioscience Inc. (SKYE) News on October 27, 2025

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

Simply Wall St.

4 months ago

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

GlobeNewswire

4 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

TipRanks

4 months ago

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

GlobeNewswire

4 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

GlobeNewswire

5 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

GlobeNewswire

5 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

GlobeNewswire

5 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ...

GuruFocus.com

6 months ago

Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

GlobeNewswire

6 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

GlobeNewswire

6 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

GlobeNewswire

6 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

GlobeNewswire

6 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

GlobeNewswire

6 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

GlobeNewswire

7 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience to Participate in SXSW Session on Obesity

GlobeNewswire

8 months ago

Skye Bioscience to Participate in SXSW Session on Obesity

We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely

Simply Wall St.

8 months ago

We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely

Skye Bioscience to Present at TD Cowen Health Care Conference

GlobeNewswire

8 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

GlobeNewswire

9 months ago

Skye Bioscience Announces Participation in February Conferences

Skye Bioscience Provides 2025 Look Ahead and Year in Review

GlobeNewswire

9 months ago

Skye Bioscience Provides 2025 Look Ahead and Year in Review

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

GlobeNewswire

a year ago

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond

TipRanks

a year ago

Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

GlobeNewswire

a year ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire

a year ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

GlobeNewswire

a year ago

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience to Announce Third Quarter 2024 Results

GlobeNewswire

a year ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

GlobeNewswire

a year ago

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

GlobeNewswire

a year ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

GlobeNewswire

a year ago

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

GlobeNewswire

a year ago

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

GlobeNewswire

a year ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

GlobeNewswire

a year ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire

a year ago

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity

GlobeNewswire

a year ago

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

GlobeNewswire

a year ago

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

GlobeNewswire

a year ago

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

GlobeNewswire

a year ago

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

GlobeNewswire

a year ago

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

GlobeNewswire

a year ago

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

GlobeNewswire

a year ago

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

a year ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

GlobeNewswire

a year ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

Business Wire

a year ago

Form 8.3 - Darktrace plc

Business Wire

a year ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

a year ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

a year ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GlobeNewswire

a year ago

Middlefield Canadian Income PCC: Net Asset Value(s)

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

a year ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

GlobeNewswire

a year ago

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience to Present at Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Skye Bioscience to Present at Jefferies Global Healthcare Conference

Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake

Simply Wall St.

a year ago

Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting

GlobeNewswire

a year ago

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

GlobeNewswire

a year ago

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

Skye Bioscience to Present at Upcoming Investment Conferences

GlobeNewswire

2 years ago

Skye Bioscience to Present at Upcoming Investment Conferences

Share on Social Networks: